The nice people at the Stem Cell Evidence Alert sent out their newsletter today. As is the case with most of their communications, much of it went over my head. But reading the abstracts gave me a little insight into some recent developments in the world of haematological malignancies.
ARTICLE OF THE MONTH
versus myeloablative conditioning in cord blood transplantation for AML
(40-60 years) across highly mismatched HLA barriers - On behalf of
Eurocord and the Cellular Therapy & Immunobiology Working Party
(CTIWP) of EBMT.